Long-Term Dosing Proves Isis’ Mipomersen Safe
This article was originally published in The Pink Sheet Daily
Executive Summary
Option to self-administer the Phase III lipid-lowering drug could boost sales.
You may also be interested in...
Isis Hits LDL Milestone In Bristol-Myers Squibb Deal
Firm talent-spots PCSK9 compound to the tune of $2 million.
Genzyme/Isis: Has ENHANCE Dulled Mipomersen's Prospects?
In early January, Genzyme nabbed one of the highest-value specialist cholesterol-busting drugs around: Phase III mipomersen, from Isis Pharmaceuticals. But given the ENHANCE-triggered questions around the value of ever-lower LDL, it's reasonable to ask whether mipomersen has a somewhat less rosy prospect in the few weeks since the deal was signed.
Genzyme, Isis Partner On Lipid Lowering Treatment Based On Antisense Technology
Genzyme calls mipomersen, currently in Phase III, a blockbuster after gaining rights in potential $1.9 billion deal.